Skip to main content
letter
. 2020 Sep 1;105(9):e465–e469. doi: 10.3324/haematol.2019.227975

Figure 2.

Figure 2.

LL-37 inhibits spontaneous and ABT-199 induced apoptosis of chronic lymphocytic leukemia cells. Peripheral blood mononuclear cells (PBMC) samples from chronic lymphocytic leukemia (CLL) patients were incubated with LL-37 (2.5-10 mM) for 48 hours (h) 37ºC. Cells were stained with PC5-anti-CD19 mAb and AnnexinV-FITC and analyzed by flow cytometry. (A) Shown are representative CD19 versus AnnexinV dot plots (blue dots: M-CLL, red dots: U-CLL) and the percentage of apoptotic cells (mean ± standard error of the mean [SEM], n=12). (B) PBMC samples from CLL patients were incubated with ABT-199 (0.01 μM) with or without LL-37 (5 mM) for 48 h at 37ºC. (C-D) Apoptosis was assessed by flow cytometry as described in (A). Depicted are representative CD19 versus AnnexinV dot plots and the percentage of apoptotic cells (mean ± standard error of the mean [SEM], n=13). Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test (P<0.05). (E) Leukemic cells were treated with ABT-199 (0.1 mM) for 18 h with or without LL-37 (5 mM). The activation of the apoptotic program was analyzed by caspase-3 cleavage and flow cytometry. Shown are representative histograms (n=5).